1. Introduction {#sec1-molecules-14-04790}
===============

4-Hydroxycoumarins (2*H*-1-benzopyran-2-ones, [Figure 1](#molecules-14-04790-f001){ref-type="fig"}) have evoked a great deal of interest due to their biological properties and characteristic conjugated molecular architecture. Many of them display important pharmacological effects, including analgesic \[[@B1-molecules-14-04790]\], anti-arthritis \[[@B2-molecules-14-04790]\], anti-inflammatory \[[@B3-molecules-14-04790]\], anti-pyretic \[[@B4-molecules-14-04790]\], anti-bacterial \[[@B5-molecules-14-04790]\], anti-viral \[[@B6-molecules-14-04790]\], and anti-cancer \[[@B7-molecules-14-04790]\] properties. 4-Hydroxy-coumarin and its derivatives have been effectively used as anticoagulants for the treatment of disorders in which there is excessive or undesirable clotting, such as thrombophlebitis \[[@B8-molecules-14-04790]\], pulmonary embolism \[[@B9-molecules-14-04790]\], and certain cardiac conditions \[[@B10-molecules-14-04790]\]. A number of comparative pharmacological investigations of the 4-hydroxycoumarin derivatives have shown good anticoagulant activity combined with low side effects and little toxicity \[[@B11-molecules-14-04790]\].

Nowadays 4-hydroxycoumarin and its derivatives are widely used anticoagulant rodenticides as well as antithrombotic agents \[[@B12-molecules-14-04790]\]. The 4-hydroxycoumarin anticoagulants are antagonists of vitamin K and their target is vitamin K 2,3-epoxide reductase in the liver microsomes. Finally, they are also useful key intermediates for many industrial products such as dyes \[[@B13-molecules-14-04790]\] and liquid crystals \[[@B14-molecules-14-04790]\].

The chemical synthesis, structural modification, and a wide variety of biological activities of 4-hydroxycoumarins have been reported in many papers \[[@B15-molecules-14-04790],[@B16-molecules-14-04790],[@B17-molecules-14-04790]\]. The goal of this review is to summarize recent synthetic approaches to 4-hydroxycoumarin derivatives and their biological activities.

2. Results and Discussion {#sec2-molecules-14-04790}
=========================

The 2*H*-1-benzopyran-2-one and tetrahydronaphthalen-1-ols skeletons are essential structural features in the second generation rodenticide 4-hydroxycoumarin derivatives. They have traditionally been coupled in acidic media. Although several improved condensation reactions of 4-hydroxy-coumarin (**1**) with compounds **8-9** using Bronsted-Lowry acids (HCl, H~2~SO~4~, *p*-TsOH) have been reported \[[@B18-molecules-14-04790],[@B19-molecules-14-04790],[@B20-molecules-14-04790],[@B21-molecules-14-04790]\], these reactions led to preferential dehydrohalogenation, resulting in low yields. Thus, an efficient coupling condition was required to obtain better yield. [Scheme 1](#molecules-14-04790-sch001){ref-type="scheme"} shows a representative retrosynthetic approach for this class of molecules. The tetrahydronaphthalen-1-ol **8** was coupled with 4-hydroxycoumarin (**1**) or 4-hydroxythiocoumarin (**2**) to generate the target 2*H*-1-benzopyran-2-one or 2*H*-1-benzothiopyran-2-one.

Our previous synthesis of flocoumafen (**5**) \[[@B18-molecules-14-04790],[@B19-molecules-14-04790]\] is summarized in [Scheme 2](#molecules-14-04790-sch002){ref-type="scheme"}. Its main reactions were Friedel-Crafts acylation, Reformatsky reaction, and dehydration. Commercially available phenylacetyl chloride (**10**) was condensed with anisole (**11**) in the presence of AlCl~3~ to afford ketone **12**, which was treated with ethyl bromoacetate to give hydroxyl ethyl ester **13** in 86% yield over two steps. Subsequent dehydroxylation of ethyl ester **13** was accomplished with triethylsilane and boron trifluoride to give the corresponding ester, which was smoothly hydrolyzed under basic conditions and cyclized using polyphosphoric acid to yield tetralone **14** in three steps. Reduction of tetralone **14** with sodium borohydride afforded secondary alcohol **15**, which was then coupled with 4-hydroxycoumarin in the presence of *p*-toluenesulfonic acid to give compound **16**. Demethylation of compound **16** was performed with hyrobromic acid in acetic acid to give phenol **17**. Phenol **17** was *O*-alkylated with freshly prepared 3-(trifluoromethyl)benzyl bromide in sodium hydride/THF to generate flocoumafen (**5**) in good yield (overall yield was 25% in eight steps).

The Ferreira group \[[@B20-molecules-14-04790]\] has developed to a new protocol for the synthesis of diphenacoum (**29**) and brodifacoum (**30**). The key step involves the stereospecific formation of one of the crucial bonds in the molecular backbone using asymmetric organocopper 1,4-addition to chiral imides. Wittig condensation of freshly prepared aldehydes **18**, **19**, and (carbethoxy)triphenylphosphonium chloride (**20**) in the presence of sodium methoxide in DMF gave the biphenyl esters **21**, **22** in 92% and 87% yield, respectively. Organocopper methodology was then successfully applied to the synthesis of butanoate. 1,4-Michael addition with compounds **21**, **22** and BnCu-TMEDA complex in the presence of TMS-Cl generated **23**, **24** in 84% and 81% yield, respectively, and then subsequent ring cyclization by using AlCl~3~ in toluene to give tetralones **25** and **26** in 88% and 86% yield, respectively. The coupling reaction between 4-hydroxycoumarin **1** and secondary alcohol **27** or brominated compound **28** under an HCl atmosphere at 160 °C 30 min provided approximately equal quantities of the *cis* and *trans* isomers of 4-hydroxycoumarin derivatives **29** and **30** in 78% and 74% yield, respectively ([Scheme 3](#molecules-14-04790-sch003){ref-type="scheme"}).

The Yang group \[[@B21-molecules-14-04790]\] reported the synthesis of novel diphenacoum analogues using base-catalyzed aldol condensation, ring cyclization, and coupling reactions. 2-Hydroxyacetophenone (**31**) was treated with aldehydes **32** or **33** under base-catalyzed aldol reaction conditions to produce ketones **34**, **35**, which were readily cyclized by phosphoric acid in ethanol to give 2-biphenylchroman-4-ones **36** and **37**, respectively. Reduction of **36** and **37** with sodium borohydride in methanol gave quantitative yields of the corresponding alcohols **38** and **39**, which were then condensed with 4-hydroxycoumarin (**1**) in 1,2-dichloroethane in the presence of a catalytic amounts of *p*-toluenesulfonic acid, to yield the target compounds **40** and **41**, respectively ([Scheme 4](#molecules-14-04790-sch004){ref-type="scheme"}).

The Danchev group \[[@B22-molecules-14-04790]\] reported a synthesis of 4-hydroxcoumarin derivatives and their anticoagulant activities. Their method involves a condensation reaction of 4-hydroxcoumarin (**1**) with unsaturated ketone **42** or substituted aromatic aldehydes **32-33** ([Scheme 5](#molecules-14-04790-sch005){ref-type="scheme"}). Warfarin type compound **43** showed similar anticoagulant effect as coumachlor or warfarin *in vivo*, while its acute toxicity was higher than that of woumachlor. Among their 4-hydroxcoumarin derivatives 3,3'-(4-chlorophenylmethylene)-bis-(4-hydroxy-2H-1-benzopyran-2-one), with low toxicity, is a prospective lead compound.

The Hamdi group \[[@B23-molecules-14-04790]\] prepared benzopyranodicoumarins **46** and **49** and evaluated their antioxidative and antibacterial activities. Aromatic aldehydes **44** containing different groups in the *ortho*-, *meta-* or *para-* positions was condensed with 4-hydroxycoumarin (**1**) in ethanol and acetic acid to generate substituted 3,3'-arylidenebis-4-hydroxycoumarins **45** and tetrakis-4-hydroxycoumarin derivatives **48.** Heating of compounds **45** and **48** in acetic anhydride transformed them into benzopyranodicoumarins **46** and **49** ([Scheme 6](#molecules-14-04790-sch006){ref-type="scheme"}).

On the other hand, the Raghunathan group \[[@B24-molecules-14-04790]\] successfully established a pyrano\[3-2c\]coumarin framework using microwave accelerated intramolecular domino Knoevenagel-hetero Diels-Alder reactions. 4-Hydroxycoumarin (**1**) was treated with 2-(3-methyl-2-butenyloxy)benzaldehyde under microwave irradiation in ethanol for 15 s to give a 97:3 ratio of pyrano\[3-2c\]coumarin **51** and pyrano\[3-2c\]chromene derivative **52** in good yield ([Scheme 7](#molecules-14-04790-sch007){ref-type="scheme"}). This methodology is very useful, providing an easy access to the pyrano\[3-2c\]coumarin skeleton found in many natural products.

The Trkovnik group \[[@B25-molecules-14-04790]\] synthesized substituted 4-hydroxycoumarins **54** and **56** from compounds **53** and **55** according to a modified Pauly and Lockemann method \[[@B26-molecules-14-04790]\], respectively. They also prepared dicoumairn type moiety **59** in good yield ([Scheme 8](#molecules-14-04790-sch008){ref-type="scheme"}).

The Swenson group \[[@B27-molecules-14-04790]\] recently published a unique procedure for preparation of 3-(*p*-azido, amino, and nitrobenzyl)-4-hydroxycoumarins **62-64** by the reaction of freshly prepared benzyl malonic acid **60** and phenol (**61**) in the presence of phosphorus trichloride and zinc chloride ([Scheme 9](#molecules-14-04790-sch009){ref-type="scheme"}). They also prepared various radiolabeled 3-substituted 4-hydroxycoumarin derivatives using commercially available \[U-^14^C\] phenol or \[U-^3^H\] in order to elucidate the binding photoaffinity. Compounds **62-64** serve as effective competitive inhibitors of the dicoumarol sensitive NADPH quinone reductase from rat liver \[[@B28-molecules-14-04790],[@B29-molecules-14-04790]\].

Recently, stereoselective synthesis has been an important topic in the synthesis of biologically active substances. Efficient asymmetric syntheses of 4-hydroxycoumarin derivatives were demonstrated by two groups. The Ferreira group \[[@B30-molecules-14-04790]\] firstly reported a highly stereo- and enantio- selective synthesis of diphenacoum (**29**) and brodifacoum (**30**). The key step involves a stereospecific 1,4-Michael addition using a chiral auxiliary and intramolecular ring cyclization. The esters **21**, **22** were transformed into acid chlorides through hydrolysis and chlorination with KOH and SOCl~2~, and subsequently reacted with the lithium anion of the chiral auxiliary to afford the chiral imides **65-68** in 72%, 74%, 73%, and 70% yield, respectively, for three steps. Asymmetric 1,4-Michael addition of imides **65-68** was accomplished with Bn-Cu-TMEDA complex in the presence of Bu~2~BOTf to give diastereoisomeric ketones **69-72**, which were effectively cyclized using trifluoromethanesulfonic acid to generate chiral tetralones **73-76** with 99% optical purity in 85%, 84%, 79%, and 80% yield, respectively. Reduction of tetralones **73-76** with sodium borohydride afforded the corresponding *cis* benzyl alcohols, which were condensed with 4-hydroxcoumarin (**1**) to give *cis*/*trans* diphenacoum and brodifacoum, respectively ([Scheme 10](#molecules-14-04790-sch010){ref-type="scheme"}). The stereoisomeric mixtures were readily separated by flash column chromatography. The configuration was established using spectroscopic analysis.

The Jorgensen group \[[@B31-molecules-14-04790]\] reported a highly economical organocatalytic asymmetric 1,4-Michael addition of 4-hydroxycoumarin and α,β--unsaturated ketones to generate the widely used anticoagulants warfarin (Coumadin) and some related important compounds ([Scheme 11](#molecules-14-04790-sch011){ref-type="scheme"}). They attempted enantioselective 1,4-Michael addition by using well known benzylideneacetophenone (**85**) and 4-hydroxycoumarin (**1**) in the presence of optically active imidazolidine catalysts **86-88** to afford enantiopure warfarin moieties with 47 to 82% ee values in 22 to 96% yields. This asymmetric one-step method could be useful for the formation of a number of biologically active compounds.

The Tagliapietra group \[[@B32-molecules-14-04790]\] developed an asymmetric two-step synthesis of non-racemic coumarin anticoagulants such like warfarin, coumachlor, and acenocoumarol through one-pot-three-component tandem Knoevenagel-hetero Diels-Alder cycloaddition reactions between *in situ* generated 3-arylidene-2,4-chromanediones **89** and isopropenyl ether **90** derived from (-)-menthol in 61% yield with 95% ee for (*S*)-warfarin, 56% yield with 93% ee for (*S*)-coumachlor, and 59% yield with 95% ee for (*S*)-acenocoumarol ([Scheme 12](#molecules-14-04790-sch012){ref-type="scheme"}). Knoevenagel adducts **91** were treated with 3N-HCl in the presence of SiO~2~ or TFA:H~2~O (19:1, v/v) as a reaction promotor to get the final asymmetric products **92** in nearly quantitative yields.

3. Biological Activity {#sec3-molecules-14-04790}
======================

A large number of 4-hydroxycoumarins and their derivatives have been synthesized and evaluated for their ability to play a positive role in the prevention of human and animal diseases. Various pharmacological activities for the representative compounds have been described in the literature ([Table 1](#molecules-14-04790-t001){ref-type="table"}). Most 4-hydroxycoumarin derivatives showed representative anticoagulant effects, while compounds **3**, **5**, **30**, **40**, **46**, and **64** exhibit a wide variety of activities including antiarthritis, anti-inflammatory, anticancer, antithrombosis, teratogenic, antibacterial, and photoaffinity effects.

Anticoagulant is the most prominent among many intriguing pharmacological effects observed for many 4-hydroxycoumarin derivatives. In particular warfarin, as first generation anticoagulant, and compounds like brodifacoum, bromadiolone, chlorophacinone, difenacoum, coumatetralyl, flocoumafen, and difethialone are effective anticoagulant rodenticides. The second generation anticoagulant rodenticides, difenacoum (**29**) and brodifacoum (**30**) showed a plasma elimination half-life of 91.7 days, while liver elimination half-lives varied from 15.8 days for coumatetralyl (**4**) to 307.4 days for brodifacoum. In general, the elimination half-lives in plasma for first-generation rodenticides were shorter than those for second-generation rodenticides. These results revealed that the so-called superwarfarins such as difenacoum (**29**), brodifacoum (**30**), flocoumafen (**5**), and difethialone (**6**) showed higher anticoagulant effects than warfarin \[[@B48-molecules-14-04790]\]. The biological activities of compounds **40** and **41** indicate potent vitamin K 2,3-epoxide reductase (VKOR) inhibition effects with IC~50~ values of 0.4 μM, comparable with warfarin. Compound **40** was shown to be 2.5-fold more potent than warfarin, while compound **41** exhibited 10 times less activity than warfarin. These biological results imply that the hydrogen bonding has a major effect on enzyme site binding \[[@B21-molecules-14-04790]\]. 4-Hydroxycoumarin derivatives **43** showed favorable anticoagulant effect compared with warfarin; especially a chlorine at the *para*-position in the aromatic ring resulted in potent anticoagulant activities compared to nitro or other halogen substituents at the *para*-position \[[@B22-molecules-14-04790],[@B49-molecules-14-04790]\]. The dicoumarol related compounds **48-49** were evaluated for antimicrobial, antioxidant activities using MIC tests and radical scavenging activities. Also, compounds **48** and **49** showed favorable antimicrobial activity compared to warfarin and similar effects to each other for the antioxidant activity. In addition, the coumarol moiety showed more potent activity than a benzopyranocoumarol moiety due to the stable configuration and favorable binding activity through hydrogen bonding in the enzyme binding site \[[@B22-molecules-14-04790]\]. 6-Bromo-4-hydroxycoumarin (**54**) and 4-hydroxy-6,7-benzocoumarin (**56**) exhibited significant anticoagulant effect with a rapid short duration. Especially 3,3'-alkylidene bis-6-bromo-4-hydroxycoumarin derivatives showed a potent anticoagulant activity *in vitro* \[[@B25-molecules-14-04790]\].

A 4-hydroxycoumarin containing an azidobenzyl group at the 3-position − 3-(*p*-azidobenzyl)-4-hydroxycoumarin (**64**)---showed an inhibition constant of 6.6 × 10^-8^ M, a value comparable to that observed for dicoumarol (1.7 × 10^-9^ M), but significantly lower than that for warfarin (3.5 × 10^-5^ M). This result implies that compound **64** can be an effective photoaffinity probe in the identification of other proteins associated with the vitamin K-dependent carboxylation system that are similarly inhibited by 4-hydroxycoumarin derivatives \[[@B46-molecules-14-04790]\].

4. Conclusions {#sec4-molecules-14-04790}
==============

The chemical syntheses and structural modifications of 4-hydroxycoumarin and its derivatives are of interest due to their biological activities and characteristic conjugated molecular architecture. This review summarized the recent synthetic approaches to 4-hydroxycoumarin derivatives and the current state of research into their biological activities.
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molecules-14-04790-t001_Table 1

###### 

Biological activities for 4-hydroxycoumarin derivatives.

  ----------------------------------------------------------------------------------------------------------------------------------
  4-Hydroxycoumarin   Biological activity                                 References
  ------------------- --------------------------------------------------- ----------------------------------------------------------
  **3**               arthritis, anti-inflammatory\                       \[[@B33-molecules-14-04790],[@B34-molecules-14-04790]\]\
                      anti-cancer, anticoagulant\                         \[[@B35-molecules-14-04790],[@B36-molecules-14-04790]\]\
                      antithrombosis                                      \[[@B37-molecules-14-04790]\]

  **4**               anticoagulant                                       \[[@B38-molecules-14-04790]\]

  **5**               anticoagulant, teratogenic                          \[[@B39-molecules-14-04790],[@B40-molecules-14-04790]\]

  **6**               anticoagulant                                       \[[@B41-molecules-14-04790]\]

  **29**              anticoagulant                                       \[[@B42-molecules-14-04790]\]

  **30**              teratogenic                                         \[[@B43-molecules-14-04790]\]

  **40**              vitamin K 2,3-epoxide reductase (VKOR) inhibitors   \[[@B21-molecules-14-04790]\]

  **41**              anticoagulant                                       \[[@B44-molecules-14-04790]\]

  **43**              anticoagulant                                       \[[@B45-molecules-14-04790]\]

  **46**              anti-bacterial                                      \[[@B23-molecules-14-04790]\]

  **54**              anticoagulant                                       \[[@B25-molecules-14-04790]\]

  **56**              anticoagulant                                       \[[@B25-molecules-14-04790]\]

  **64**              photoaffinity                                       \[[@B46-molecules-14-04790]\]

  **92**              anticoagulant                                       \[[@B47-molecules-14-04790]\]
  ----------------------------------------------------------------------------------------------------------------------------------
